From L-R: Gerard Caelles, Miquel Vila-Perelló and Silvia Frutos (SpliceBio)
Some genes are too large to fit into AAV vectors. UCB, Novartis back $57M idea to deliver them in parts instead
Of all the major limitations of adeno-associated viruses (AAV) as a vector for gene therapy, one is particularly well-known and indisputable: They can only carry …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
